Skip to content

Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project

Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07005947
Acronym
LCCS
Enrollment
237
Registered
2025-06-05
Start date
2023-11-30
Completion date
2026-06-30
Last updated
2026-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute COVID-19, Diabetic Neuropathy, Long COVID-19, Postural Orthostatic Tachycardia Syndrome (POTS)

Keywords

COVID, Diabetic Neuropathy, Postural orthostatic tachycardia syndrome, POTS

Brief summary

This is a prospective, longitudinal study involving 300 participants for a single visit to compare Long COVID-19 neurocutaneous biosignatures with those of other disorders affecting the sensory and autonomic nervous system.

Detailed description

This is a prospective, longitudinal study involving 300 participants for a single visit to compare Long COVID-19 neurocutaneous biosignatures with those of other disorders affecting the sensory and autonomic nervous system. The evaluations will include clinical assessments, neurologic exams, patient reported outcome surveys, and skin biopsies from three locations. Data will be collected on the amount of P-SYN in cutaneous nerve fibers. The cohorts of interest are as follows: 1. 100 participants with Long COVID-19 defined by NIH PASC criteria 2. 100 participants with acute COVID-19 who tested positive for COVID-19 without persistent symptoms defined WHO criteria 3. 50 participants with postural orthostatic tachycardia syndrome (POTS) 4. 50 participants with diabetic neuropathy There are no plans for additional visits at this time. If interested to learn more about this study, please complete the form here for someone to contact you. "here" would take you to the said form.

Interventions

None listed

Sponsors

CND Life Sciences
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

, just one of the following: * Long COVID-19 defined by NIH PASC criteria OR * Acute COVID-19 who tested positive for COVID-19 without persistent symptoms OR * Postural orthostatic tachycardia syndrome (POTS) OR * Diabetic neuropathy

Exclusion criteria

* Clinical evidence of severe peripheral vascular disease * History of ulceration, poor wound healing or vascular claudication * History of allergic reaction to local anesthesia (for biopsy collection) * Use of oral anticoagulants (aspirin or Plavix alone is allowed) * History of a bleeding disorder

Design outcomes

Primary

MeasureTime frameDescription
Pathology and nervous system changes that occur in patients suffering from sensory and autonomic function changesCurrent - December 31,2025This is a single site study of subjects with Long COVID, subject with a previous positive COVID test without persistent symptoms, and POTS subjects and diabetics. Neurocutaneous biosignatures will provide insight into the pathology and nervous system changes that occur in patients suffering from sensory and autonomic function changes.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 3, 2026